Medytox Achieves 61.6 Billion KRW in Sales and 6.3 Billion KRW in Operating Profit in Q2

First-Ever Achievement: Over 60 Billion KRW in Sales for Two Consecutive Quarters

On August 11, Medytox, a biopharmaceutical company, announced its second-quarter earnings, reporting sales of 61.6 billion KRW, operating profit of 6.3 billion KRW, and net profit of 8.2 billion KRW. Compared to the previous quarter, sales decreased by 3.6%, but operating profit and net profit increased by 15.4% and 144.5%, respectively. When compared to the same period last year, sales, operating profit, and net profit declined by 5.2%, 55.9%, and 27.8%, respectively.

Medytox achieved sales exceeding 60 billion KRW for two consecutive quarters for the first time in its history, thanks to steady revenue from its core businesses such as toxin and filler products. In particular, exports of botulinum toxin products grew by 17% compared to the previous quarter and by 16% year-on-year, continuing their upward trend. In the second half of the year, the company aims to significantly increase sales by expanding the list of overseas countries where Newlux is registered. The company also expects that the recent conclusion of some lawsuits, which has led to a decline in selling, general, and administrative expenses, will have a positive impact on future profit improvement.

A Medytox representative stated, "With Newlux, which has established strong brand recognition in the domestic market, accelerating its overseas expansion in the second half of the year, we expect to drive further sales growth. We will also make every effort to complete ongoing projects, such as the submission of a U.S. FDA application for our next-generation liquid toxin product MT10109L, which is being developed for the global market, and obtaining approval for MT921, the world's first deoxycholic acid-based fat-dissolving injectable."